Health
WMD: US$45bn will be needed in 4 years to meet global malaria targets -WHO
By Wumi Tewogbade, Abuja
The World Health Organization (WHO) on Wednesday, said about US$45 billion would be needed in the next 4 years to meet global malaria targets.
This was contained in a message to commemorate the World Malaria Day (WMD), issued by WHO Regional Director for Africa, Dr
Mohamed Janabi, in Abuja.
The theme for 2026 WMD, is ‘ Driven to End Malaria: Now We Can. Now We Must’.
He lamented that the tiny mosquito continues to cause enormous harm. Every year, malaria kills
hundreds of thousands of people, most of them young African children.
He said, “Yet today we can also say something once unimaginable. We have the commitment, knowledge and tools to dramatically reduce malaria illness and deaths, eventually ending malaria as a public health threat”.
Speaking on the theme he said, “The theme of this year’s World Malaria Day is Driven to End Malaria: Now We Can.
Now We Must. This is both a message of hope and an urgent call to action.
Across the African Region, countries are showing stronger leadership, increasing
domestic investment and using innovation to protect those most at risk”.
He noted, “The malaria
response is entering a new phase shaped by country ownership, smarter data use, stronger community engagement and transformative new tools. Elimination is no longer
a distant aspiration. It is an achievable goal if we act decisively, now.
“Our Region still carries the world’s heaviest malaria burden. In 2024 alone, nearly 600,000 lives were lost in Africa. Three-quarters of those deaths were among young children. These preventable deaths remind us why progress cannot wait.
“There are encouraging signs of momentum. More than ten countries have increased
domestic financing for malaria programmes since January 2025. Twenty-five countries
are rolling out malaria vaccines, helping protect around 10 million children each year”.
He said the next-generation mosquito nets is designed to overcome insecticide resistance now
account for the vast majority of newly distributed nets.
“Digital technologies are improving
our ability to predict, detect and respond to outbreaks. Plus new vector control innovations are expanding our toolbox. .
“But progress is not guaranteed. Funding gaps continue to slow the response. At least US$45 billion will be needed between 2026 and 2030 to meet global malaria targets. Insecticide resistance is widespread. Drug resistance is emerging in some settings.
“Climate variability is changing transmission patterns. And humanitarian crises and displacement are increasing vulnerability”.
The WHO boss noted that, it is possible to overcome the challenges, because there are stronger political commitment, better data, more
engaged communities and more powerful tools than ever before.
“Now we must—because when investment declines and programmes weaken, malaria
returns quickly, reversing hard-won gains and costing lives. To seize this moment, five priorities are essential:
“First, countries must continue to lead the malaria response with strong national ownership. When governments prioritize malaria as a dividend of national development and mobilize domestic resources, they lay the foundation
for sustainable impact” he noted.
Health
Nigeria to Benefit from Anti HIV Injection Drug, Lenacapavir, Courtesy of USA
By Isa Abdul, Abuja
The first generic version of lenacapavir, a twice-yearly injection used to prevent HIV infection, has been given tentative approval by the U.S. Food and Drug Administration (FDA), in a major development for global HIV prevention.
The generic drug which has been developed by India’s Dr Reddy’s Laboratories, and is expected to cost about $40 per person annually, will be made available across 120 low- and middle-income countries, including Nigeria.
The injection has demonstrated near-total effectiveness in clinical trials, offering an alternative to daily HIV prevention pills. The approval is expected to accelerate access to affordable prevention options, although local regulatory processes, funding and distribution remain key to its rollout.
Health
NCDC Says Two Suspected Ebola Cases In Adamawa Test Negative
By Michael Lim
The Nigeria Centre for Disease Control (NCDC) has disclosed that the two suspected Ebola cases reported in Yola, Adamawa State, have tested negative following two rounds of laboratory testing.
The Agency noted in a statement that it is working with the Adamawa State Government to investigate the cases, which were isolated and tested.
The NCDC clarified that the index case previously confirmed in the Federal Capital Territory remains the only confirmed Ebola case reported in Nigeria.
It urged Nigerians to remain calm and rely on official government and public health channels for accurate information.
The Agency further advised anyone experiencing symptoms such as fever, severe weakness, headache, muscle pain, vomiting, diarrhoea or unexplained bleeding, particularly after possible exposure, to seek immediate medical attention and provide healthcare workers with relevant travel and contact history.
Health
NCDC: Two Suspected Ebola Cases in North-East Nigeria: Investigations, Lab Tests Ongoing
By Michael Lim
Two individuals have been isolated by health authorities following suspicion that they may be infected by Ebola disease in Nigeria’s North-East region as they are being subjected to investigations and lab tests.
An update on the disease situation by the Nigeria Centre for Disease Control and Prevention (NCDC), said contact identification and listing were ongoing, while samples from the suspected cases were being subjected to laboratory testing.
It clarified that the classification of the individuals as suspected cases did not mean they had tested positive for Ebola, noting that confirmation would depend on laboratory results.
The public was advised to maintain proper hand hygiene, practise enhanced sanitation and follow preventive guidance issued by public health authorities.
The update added that further information would be provided as verified details become available.
